Skip to main content
. 2023 Feb 27;14:1071. doi: 10.1038/s41467-023-35962-x

Fig. 2. Acquired alterations in osimertinib-treated patients and in chemotherapy-treated patients.

Fig. 2

Tile plots indicating A acquired alterations in osimertinib-treated patients (n = 78) and B acquired alterations in chemotherapy-treated patients (n = 25) from the AURA3 trial. Source data are provided in the Supplementary Data 1 file. *C797S or C797G; L792F or L792H. EGFR epidermal growth factor receptor.